Work

Abstract 6453: Serum pharmacodynamic biomarkers of IPI/NIVO/RELA plus sarilumab in Stage III-IV melanoma: Stage 1 results of a Simon Phase II trial (NCT05428007)

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-6453

Authors: Teruyuki Mizutani, Amrutesh Puranik, Inderjit Mehmi, Judith Goldberg, Maya Dimitrova, Perla Arriola, Stanzin Idga, Xiaochun Li, Benjamin Levinson, Justine Cohen, Elizabeth I. Buchbinder, Donald Lawrence, Alissa Kalyan, Morgan Simons, F. Stephen Hodi, Ryan J. Sullivan, Omid Hamid, Michelle Krogsgaard, Janice M. Mehnert

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Angeles Clinic and Research Institute, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148645815

Cites:

Cited by:

Related to: